Renal disease is a severe and increasing problem with chronic kidney disease (CKD) associated with increasing incidence of obesity and metabolic disease. Current treatments for diabetic kidney disease are limited and generally ineffective, highlighting the need for innovative therapeutic strategies. Photobiomodulation is one such potential therapy. PBM is known to modulate cellular function, suppress inflammation, restore balance redox, and improve mitochondrial activity, all of which are hallmarks of CKD. Here we highlight photobiomodulation treatment for CKD in in vitro and in vivo models, with implications for photobiomodulation mechanisms. In vitro results showed that low-dose photobiomodulation resulted in over-expression of fibronectin and tumour necrosis factor and down-regulation of glutathione peroxidase while high-dose photobiomodulation did not. Similarly, in vivo results also showed that low but not high-dose PBM improved kidney function, decreased blood urea, albumin, albumin-creatinine ratio and other markers of CKD. There were significant microbiome changes associated with photobiomodulation treatment.
Chronic kidney disease (CKD) is a worldwide public health problem, resulting in a significant burden on the health system. PBM is effective in mitigating inflammation, mitochondrial dysfunction, and oxidative stress, all of which are factors inherent in CKD. The aim of this study was to identify the direct effects of PBM in an in-vitro model of CKD. In vitro human proximal tubular cells (HK2 cells) were pre-treated with low (1.38 J/cm2) or high dosage (2.75J/cm2) of PBM. Cells were then incubated with TGF-β1 (2 ng/ml) for 48 hours with or without PBM irradiation every 24 hours. The SHAM groups were processed under the exact same conditions except in the absence of PBM irradiation. The expression levels of inflammatory markers monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fibrotic marker fibronectin (FN), antioxidative markers superoxide dismutase 1 (SOD1) and SOD2 were measured by qRT-PCR or ELISA The results showed that TGF-β1 significantly increased MCP-1, TNF-α, and fibronectin mRNA expression in HK2 cells, which was significantly reversed by the low dosage of PBM (0.45 J/cm2, P<0.05), but not the higher dosage of PBM (0,9 J/cm2) when compared with the SHAM control group. The dose-response characteristics of PBM observed in this study followed the biphasic pattern. In conclusion, the present study suggests that PBM directly reduced inflammation and fibrosis in kidney tubular cells when used at the appropriate dose.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.